Tyra Biosciences, Inc. (NASDAQ:TYRA) Receives $46.00 Consensus Price Target from Brokerages

Tyra Biosciences, Inc. (NASDAQ:TYRA) has received a consensus rating of “Moderate Buy” from the fifteen research firms that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, twelve have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $47.00.

Several brokerages recently issued reports on TYRA. Piper Sandler lifted their price target on shares of Tyra Biosciences from $42.00 to $56.00 and gave the company an “overweight” rating in a report on Friday, March 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Tyra Biosciences in a report on Monday, April 20th. Guggenheim began coverage on shares of Tyra Biosciences in a report on Tuesday, April 14th. They set a “buy” rating and a $54.00 price target for the company. Cantor Fitzgerald began coverage on shares of Tyra Biosciences in a report on Tuesday, February 24th. They set an “overweight” rating for the company. Finally, Canaccord Genuity Group began coverage on shares of Tyra Biosciences in a report on Monday, April 6th. They set a “buy” rating and a $50.00 price target for the company.

Insider Buying and Selling at Tyra Biosciences

In other Tyra Biosciences news, Director Gilla Kaplan sold 14,295 shares of the business’s stock in a transaction dated Wednesday, March 25th. The shares were sold at an average price of $36.97, for a total value of $528,486.15. Following the completion of the transaction, the director directly owned 28,231 shares of the company’s stock, valued at approximately $1,043,700.07. The trade was a 33.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 12.50% of the company’s stock.

Hedge Funds Weigh In On Tyra Biosciences

A number of institutional investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Tyra Biosciences by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,594 shares of the company’s stock worth $68,000 after acquiring an additional 534 shares during the last quarter. AQR Capital Management LLC raised its stake in shares of Tyra Biosciences by 2.0% in the fourth quarter. AQR Capital Management LLC now owns 28,631 shares of the company’s stock worth $753,000 after acquiring an additional 562 shares during the last quarter. MetLife Investment Management LLC raised its stake in shares of Tyra Biosciences by 5.0% in the fourth quarter. MetLife Investment Management LLC now owns 15,356 shares of the company’s stock worth $404,000 after acquiring an additional 725 shares during the last quarter. Virtus Investment Advisers LLC raised its stake in shares of Tyra Biosciences by 6.7% in the fourth quarter. Virtus Investment Advisers LLC now owns 11,756 shares of the company’s stock worth $309,000 after acquiring an additional 741 shares during the last quarter. Finally, Hilton Head Capital Partners LLC bought a new position in shares of Tyra Biosciences in the first quarter worth about $30,000. 84.14% of the stock is owned by institutional investors.

Tyra Biosciences Stock Performance

Shares of Tyra Biosciences stock opened at $28.32 on Tuesday. Tyra Biosciences has a twelve month low of $8.98 and a twelve month high of $40.65. The firm has a market cap of $1.68 billion, a P/E ratio of -12.99 and a beta of 0.75. The firm’s 50-day simple moving average is $32.67 and its 200-day simple moving average is $31.22.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.04). On average, equities analysts forecast that Tyra Biosciences will post -2.68 earnings per share for the current fiscal year.

About Tyra Biosciences

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.